logo
Products
Services
Resources
Selection Guides
About
iFluor® 488 Anti-human CD56 Antibody
B-A19
B-A19 is an anti-human monoclonal antibody that targets the CD56 antigen. CD56 (alternatively called NKH1 or NCAM-1) is a single-pass type i membrane protein that is expressed on the surface of cells like NK cells and T cells. CD56 has been associated with important biological processes like axon guidance, especially commissural neuron axon guidance. In addition, it plays a role in essential cellular pathways, for instance, the regulation of semaphorin-plexin signaling pathway and interferon-gamma-mediated signaling pathway. From a research standpoint, it is of biological interest due to its association with essential macromolecules/ligands such as Heparin sulfate. CD56 is a fairly uncommon antibody target, with a little more than 10000 publications in the last decade. Even still, CD56 has a variety of applications in research, often serving as a phenotypic marker for differentiating cell types in flow cytometric applications. This antibody was purified through affinity chromatography and conjugated to iFluor® 488 (ex/em = 491/516 nm). It is compatible with the 488 nm laser and 530/30 nm bandpass filter (for example, as in the BD FACSCanto™ II).
product image
CatalogSize
Price
Quantity
10560050100 tests
Price
10560051500 tests
Price
 
Antibody properties

Other namesLeu-19, NKH1, NCAM1
CloneB-A19
HostMouse
IsotypeIgG1
ReactivityHuman
ApplicationFlow Cytometry (FACS), Fluorescence Imaging
Spectral properties

Correction factor (260 nm)0.21
Correction factor (280 nm)0.11
Extinction coefficient (cm -1 M -1)
75000
1
Excitation (nm)491
Emission (nm)516
Quantum yield
0.9
1
Usage and storage

Intended useResearch Use Only (RUO)
Contact us

Telephone
Fax
Emailsales@aatbio.com
InternationalSee distributors
Bulk requestInquire
Custom sizeInquire
Technical SupportContact us
Request quotationRequest
Purchase orderSend to sales@aatbio.com
ShippingStandard overnight for United States, inquire for international
Page updated on August 12, 2026